NCT01159249 - Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes | Biotech Hunter

Enrollment

245

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Type 2 Diabetes

Interventions

DRUG

Vildagliptin

Trial Locations (24)

274-0805

Novartis Investigative Site, Hunabashi

818-0036

Novartis Investigative Site, Chikushino-shi

819-1102

Novartis Investigative Site, Itoshima-shi

963-8851

Novartis Investigative Site, Kōriyama

658-0064

Novartis Investigative Site, Kobe

210-0852

Novartis Investigative Site, Kawasaki

212-0024

Novartis Investigative Site, Kawasaki

221-0065

Novartis Investigative Site, Yokohama

221-0077

Novartis Investigative Site, Yokohama

598-0048

Novartis Investigative Site, Izumisano

357-0024

Novartis Investigative Site, Hannou

355-0328

Novartis Investigative Site, Hiki-Gun

332-0012

Novartis Investigative Site, Kawaguchi

343-0826

Novartis Investigative Site, Koshigaya

359-1161

Novartis Investigative Site, Tokorozawa

134-0084

Novartis Investigative Site, Edogawa-ku

192-0046

Novartis Investigative Site, Hachiōji

125-0041

Novartis Investigative Site, Katsushika-ku

108-0075

Novartis Investigative Site, Minato-ku

141-0032

Novartis Investigative Site, Shinagawa-ku

171-0021

Novartis Investigative Site, Toshima-ku

807-0857

Novartis Investigative Site, Fukuoka

816-0094

Novartis Investigative Site, Fukuoka

819-0168

Novartis Investigative Site, Fukuoka